Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study.
HIV
early start
first-line antiretroviral treatment
genotypic-tesistance test
rapid ART
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
27
03
2022
received:
28
07
2021
accepted:
30
03
2022
pubmed:
1
4
2022
medline:
16
6
2022
entrez:
31
3
2022
Statut:
ppublish
Résumé
Rapid start of antiretroviral therapy (ART) pending genotypic resistance test (GRT) has been recently proposed, but the effectiveness of this strategy is still debated. The rate of virological success (VS), defined as HIV-RNA < 50 copies/ml, with and without GRT was compared in drug-naïve individuals enrolled in the Italian ARCA cohort who started ART between 2015 and 2018. 521 individuals started ART: 397 without GRT (pre-GRT group) and 124 following GRT (post-GRT group). Overall, 398 (76%) were males and 30 (6%) were diagnosed with AIDS. In the pre-GRT group, baseline CD4+ cell counts were lower (p < 0.001), and viral load was higher (p < 0.001) than in the post-GRT group. The estimated probability of VS in pre-GRT versus post-GRT group was 72.54% (CI
Identifiants
pubmed: 35355293
doi: 10.1002/jmv.27754
pmc: PMC9321101
doi:
Substances chimiques
Anti-HIV Agents
0
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3890-3899Informations de copyright
© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
J Antimicrob Chemother. 2009 Sep;64(3):616-24
pubmed: 19620134
Infect Drug Resist. 2020 Jul 14;13:2291-2300
pubmed: 32765005
HIV Med. 2019 Mar;20 Suppl 1:3-11
pubmed: 30724450
J Med Virol. 2022 Aug;94(8):3890-3899
pubmed: 35355293
AIDS. 2020 Jan 1;34(1):91-101
pubmed: 31634196
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Expert Rev Anti Infect Ther. 2014 Jan;12(1):13-29
pubmed: 24308712
AIDS. 2010 Jan 2;24(1):123-37
pubmed: 19770621
Clin Infect Dis. 2021 Oct 5;73(7):e2134-e2141
pubmed: 33095848
HIV Med. 2018 Oct;19(9):619-628
pubmed: 29932313
N Engl J Med. 2009 Apr 30;360(18):1815-26
pubmed: 19339714
J Antimicrob Chemother. 2020 Nov 1;75(11):3311-3318
pubmed: 32728703
J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):484-491
pubmed: 29293156
J Infect Dis. 2021 Mar 3;223(5):866-875
pubmed: 32644119
Antiviral Res. 2019 Sep;169:104552
pubmed: 31283942
Lancet Infect Dis. 2014 Apr;14(4):281-90
pubmed: 24602844
Top Antivir Med. 2019 Sep/Oct;27(3):111-121
pubmed: 31634862
PLoS Med. 2016 May 10;13(5):e1002015
pubmed: 27163694
J Med Virol. 2014 Oct;86(10):1648-55
pubmed: 25042976
Antivir Ther. 2020;25(2):61-71
pubmed: 32118584
PLoS Med. 2017 Jul 25;14(7):e1002357
pubmed: 28742880
PLoS One. 2009;4(3):e4724
pubmed: 19266092
Clin Infect Dis. 2020 Mar 17;70(7):1353-1363
pubmed: 31055599
J Clin Virol. 2019 Jul;116:23-28
pubmed: 31075548
Curr Opin HIV AIDS. 2016 Sep;11(5):527-536
pubmed: 27367780
J Antimicrob Chemother. 2017 Oct 1;72(10):2837-2845
pubmed: 29091206
Arch Intern Med. 2011 Sep 26;171(17):1560-9
pubmed: 21949165
N Engl J Med. 2010 Jul 15;363(3):257-65
pubmed: 20647201
Ann Intern Med. 2011 Apr 19;154(8):509-15
pubmed: 21502648